- Home
- VGZ vs CHRS Comparison
VGZ vs CHRS Comparison
Compare VGZ & CHRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- VGZ
- CHRS
- Stock Information
- Founded
- VGZ 1983
- CHRS 2010
- Country
- VGZ United States
- CHRS United States
- Employees
- VGZ N/A
- CHRS N/A
- Industry
- VGZ
- CHRS Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- VGZ
- CHRS Health Care
- Exchange
- VGZ Nasdaq
- CHRS Nasdaq
- Market Cap
- VGZ 171.5M
- CHRS 159.2M
- IPO Year
- VGZ N/A
- CHRS 2014
- Fundamental
- Price
- VGZ $1.84
- CHRS $1.29
- Analyst Decision
- VGZ Strong Buy
- CHRS Strong Buy
- Analyst Count
- VGZ 1
- CHRS 4
- Target Price
- VGZ $3.00
- CHRS $4.51
- AVG Volume (30 Days)
- VGZ 1.1M
- CHRS 1.3M
- Earning Date
- VGZ 10-22-2025
- CHRS 11-05-2025
- Dividend Yield
- VGZ N/A
- CHRS N/A
- EPS Growth
- VGZ N/A
- CHRS N/A
- EPS
- VGZ N/A
- CHRS 1.55
- Revenue
- VGZ N/A
- CHRS $272,209,000.00
- Revenue This Year
- VGZ N/A
- CHRS N/A
- Revenue Next Year
- VGZ N/A
- CHRS $126.00
- P/E Ratio
- VGZ N/A
- CHRS $0.83
- Revenue Growth
- VGZ N/A
- CHRS 52.33
- 52 Week Low
- VGZ $0.47
- CHRS $0.66
- 52 Week High
- VGZ $1.84
- CHRS $2.43
- Technical
- Relative Strength Index (RSI)
- VGZ 85.79
- CHRS 62.30
- Support Level
- VGZ $1.31
- CHRS $1.26
- Resistance Level
- VGZ $1.42
- CHRS $1.40
- Average True Range (ATR)
- VGZ 0.09
- CHRS 0.08
- MACD
- VGZ 0.05
- CHRS 0.00
- Stochastic Oscillator
- VGZ 100.00
- CHRS 64.52
About VGZ Vista Gold Corp
Vista Gold Corp is a gold mining company. It is engaged in the evaluation, acquisition, exploration, and advancement of gold exploration and potential development projects. The company evaluate, acquire, explore and advance gold exploration and potential development projects for gold production or value adding strategic transactions. The Company has one reportable segment: Australia. The Australia segment conducts exploration, development, care and maintenance activities at Vista's asset, the Mt Todd gold project in Northern Territory, Australia.
About CHRS Coherus BioSciences Inc.
Coherus Oncology Inc is a fully integrated commercial-stage inventive oncology company with an approved next-generation PD-1 inhibitor, LOQTORZI, and a pipeline that includes two mid-stage clinical candidates targeting liver, lung, head & neck, and other cancers. Its strategy is to expand the use of LOQTORZI in NPC and advance the development of new indications for LOQTORZI in combination with both its pipeline candidates as well as its industry partners, driving synergies from proprietary combinations, including first-in-class anticancer agents. Its portfolio includes LOQTORZI, CHS-114, and Casdozokitug.